Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

出版年份 2016 全文链接

标题

作者

关键词

Mild Alzheimer's disease, Solanezumab, Clinical trial, Phase 3, Cognition, Function, Safety, Monoclonal antibody, EXPEDITION, Target engagement, Amyloid-β peptide, LZAM, LZAN

出版物

Alzheimers & Dementia

Volume 12, Issue 2, Pages 110-120

出版商

Elsevier BV

发表日期

2015-08-02

DOI

10.1016/j.jalz.2015.06.1893

向作者/读者发起求助以获取更多资源

Protocol

在线求助

Reagent

在线求助

Reprint

联系作者

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More